WO1999048461A3 - Substituted aromatic compounds for treatment of antibiotic resistant infections - Google Patents

Substituted aromatic compounds for treatment of antibiotic resistant infections Download PDF

Info

Publication number
WO1999048461A3
WO1999048461A3 PCT/US1999/006494 US9906494W WO9948461A3 WO 1999048461 A3 WO1999048461 A3 WO 1999048461A3 US 9906494 W US9906494 W US 9906494W WO 9948461 A3 WO9948461 A3 WO 9948461A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
aromatic compounds
substituted aromatic
antibiotic resistant
resistant infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/006494
Other languages
French (fr)
Other versions
WO1999048461A2 (en
Inventor
William Y Ellis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of the Army
Original Assignee
United States Department of the Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of the Army filed Critical United States Department of the Army
Priority to AU30126/99A priority Critical patent/AU3012699A/en
Priority to EP99911497A priority patent/EP1066035A4/en
Priority to JP2000537515A priority patent/JP2002507557A/en
Priority to CA002325689A priority patent/CA2325689A1/en
Priority to GB9909183A priority patent/GB2333454B/en
Publication of WO1999048461A2 publication Critical patent/WO1999048461A2/en
Publication of WO1999048461A3 publication Critical patent/WO1999048461A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to compounds of general formula (Y) wherein A is an aromatic hydrocarbon ring system and R1 is a carbon bound directly to an oxygen and is also bound to a nitrogen through a saturated carbon and wherein at least one of R2, R3 and R4 is an electron-rich substituent. The active agents are useful for treating patients suffering from infections including gram positive organisms, such as streptococcus, staphylococcus, anthracis, gram negative bacteria such as neisseria species, yeasts and mycobacterium. They are effective against strains which have shown resistance to other antimicrobial agents.
PCT/US1999/006494 1998-03-26 1999-03-25 Substituted aromatic compounds for treatment of antibiotic resistant infections Ceased WO1999048461A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU30126/99A AU3012699A (en) 1998-03-26 1999-03-25 Substituted aromatic compounds for treatment of antibiotic resistant infections
EP99911497A EP1066035A4 (en) 1998-03-26 1999-03-25 SUBSTITUTED AROMATIC COMPOUNDS FOR TREATING ANTIBIOTIC-RESISTANT INFECTIONS.
JP2000537515A JP2002507557A (en) 1998-03-26 1999-03-25 Substituted aromatic compounds for the treatment of antibiotic resistant infections
CA002325689A CA2325689A1 (en) 1998-03-26 1999-03-25 Substituted aromatic compounds for treatment of antibiotic resistant infections
GB9909183A GB2333454B (en) 1998-03-26 1999-03-25 Substituted aromatic compounds for treatment of antibiotic resistant infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7938398P 1998-03-26 1998-03-26
US60/079,383 1998-03-26

Publications (2)

Publication Number Publication Date
WO1999048461A2 WO1999048461A2 (en) 1999-09-30
WO1999048461A3 true WO1999048461A3 (en) 1999-12-16

Family

ID=22150207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006494 Ceased WO1999048461A2 (en) 1998-03-26 1999-03-25 Substituted aromatic compounds for treatment of antibiotic resistant infections

Country Status (6)

Country Link
EP (1) EP1066035A4 (en)
JP (1) JP2002507557A (en)
AU (1) AU3012699A (en)
CA (1) CA2325689A1 (en)
GB (1) GB2333454B (en)
WO (1) WO1999048461A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241917B2 (en) 2003-03-17 2016-01-26 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002326375B2 (en) 2001-03-08 2006-12-21 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers as anti-infective agents
DE10316081A1 (en) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie New compounds with antibacterial activity
DE102010055322A1 (en) * 2010-12-21 2012-06-21 Christian-Albrechts-Universität Zu Kiel Antibacterial and antifungal substances
AR111295A1 (en) 2017-03-20 2019-06-26 Forma Therapeutics Inc PIRROLOPIRROL COMPOSITIONS AS PIRUVATO QUINASA ACTIVATORS (PKR)
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
MX2022003025A (en) 2019-09-19 2022-04-07 Forma Therapeutics Inc ACTIVATION OF PYRUVATE KINASE R.
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461078A (en) * 1991-04-12 1995-10-24 British Technology Group Limited Anti-cancer compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327022A (en) * 1973-08-16 1982-04-27 Sterling Drug Inc. Heterocyclic alkyl naphthols
IL60530A (en) * 1979-08-16 1984-10-31 American Cyanamid Co Animal feed compositions useful as growth promotors and for reduction of fat in animals,comprising phenylethanolamine derivatives and certain such novel compounds
WO1997007792A1 (en) * 1995-08-25 1997-03-06 Department Of The Army, Us Government Desbutylhalofantrine compositions and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461078A (en) * 1991-04-12 1995-10-24 British Technology Group Limited Anti-cancer compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1066035A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241917B2 (en) 2003-03-17 2016-01-26 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof

Also Published As

Publication number Publication date
GB9909183D0 (en) 1999-06-16
WO1999048461A2 (en) 1999-09-30
GB2333454B (en) 2000-08-09
EP1066035A2 (en) 2001-01-10
JP2002507557A (en) 2002-03-12
CA2325689A1 (en) 1999-09-30
GB2333454A (en) 1999-07-28
EP1066035A4 (en) 2001-05-09
AU3012699A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
WO2005014585A8 (en) Halogenated quinazolinyl nitrofurans as antibacterial agents
WO2000034265A3 (en) Quinoline-indole antimicrobial agents
PL319873A1 (en) Antibacterial phenyloxazolydinones
PL404913A1 (en) Compound of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole
CA2349338A1 (en) Novel macrolide antibiotics
TR200102129T2 (en) Carbamate and carbazate ketolid antibiotics.
BR9813248A (en) Processes for limiting the growth of a microorganism, for disinfecting a surface and for limiting the growth of a virus, a bacterium and/or a fungus, composition, and, metal-containing compound
CA2327775A1 (en) 15-membered lactams ketolides with antibacterial activity
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
CA2160243A1 (en) 36-derivatives of rifamycins and their use as antimicrobial agents
HUP0004793A2 (en) Processes for purifying and using alatrofloxacin mesylate and parenteral compositions containing these compounds
WO2005012320A3 (en) Novel lincomycin derivatives possessing antimicrobial activity
WO2003101382A3 (en) Compounds useful in the treatment of anthrax and inhibiting lethal factor
MXPA06000691A (en) Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof.
GB8507528D0 (en) Basis monocarboxyamide derivatives
TR200102234T2 (en) Process for the preparation of pseudomonic acid A antibiotic by microbiological method
WO2004016632A3 (en) Lincomycin derivatives possessing antibacterial activity
DE60006690D1 (en) ANTIBIOTIC CAPRAZAMYCINS AND METHOD FOR THE PRODUCTION THEREOF
CA2380455A1 (en) 9a-azalides with antibacterial activity
WO2004060272A3 (en) Delivery of peroxide-generating enzymes to the vaginal tract
WO2004058182A3 (en) Use of synergistic bacteriophage lytic enzymes for prevention and treatment of bacterial infections
WO2004004646A3 (en) O-derivatized nocathiacin derivatives
WO2003101405A3 (en) Aminoglycoside antibiotics and methods of using same
Gerberick et al. In vitro susceptibility of Pseudomonas aeruginosa to carbenicillin, glycine, and ethylenediaminetetraacetic acid combinations
Williams et al. Mechanisms by which imipenem may overcome resistance in gram-negative bacilli

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA GB JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA GB JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2325689

Country of ref document: CA

Ref country code: CA

Ref document number: 2325689

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 537515

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 30126/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999911497

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999911497

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999911497

Country of ref document: EP